An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up

Cancer

Volumn 95, Issue 10, 2002, Pages 2126-2135

  Vicini, Frank A ^a,i   Martinez, Alvaro ^a   Hanks, Gerald ^b   Hanlon, Alex ^b   Miles, Brian ^c   Kernan, Ken ^c   Beyers, David ^d   Ragde, Haakon ^e   Forman, Jeffrey ^f   Fontanesi, James ^f   Kestin, Larry ^a   Kovacs, Gyorgy ^g   Denis, Louis ^h   Slawin, Kevin ^c   Scardino, Peter ^c  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d Arizona Oncology Services   (United States)

^e Grado Ragde Clinic   (United States)

^f WAYNE STATE UNIVERSITY   (United States)

^g UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^h Oncology Centre of Antwerp   (Belgium)

ⁱ NONE   (United States)

Author keywords

Prostate carcinoma; Prostatic specific antigen; Radiation therapy; Surgery

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; ARTICLE; CALCULATION; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; RISK ASSESSMENT; SCORING SYSTEM; TREATMENT OUTCOME;

ACTUARIAL ANALYSIS; AGED; BRACHYTHERAPY; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 0037110690     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10919     Document Type: Article

References (35)

1. Fowler FJ Jr., McNaughton CM, Albertsen PC, Zietman A, Elliott DB, Barry MJ. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA. 2000;283:3217-3222.
2. Albertsen PC, Albertsen PC. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. J Urol. 2001;165:731-732.
3. Kestin LL, Martinez AA, Stromberg JS, et al. Matched-pair analysis of conformal high-dose-rate brachytherapy boost versus external-beam radiation therapy alone for locally advanced prostate cancer. J Clin Oncol. 2000;18:2869-2880.
4. Merrick GS, Butler WM, Lief JH, Dorsey AT. Is brachytherapy comparable with radical prostatectomy and external-beam radiation for clinically localized prostate cancer? Tech Urol. 2001;7:12-19.
5. Beyer DC, Brachman DG. Failure free survival following brachytherapy alone for prostate cancer: Comparison with external beam radiotherapy. Radiother Oncol. 2000;57:263-267.
6. Lederman GS, Cavanagh W, Albert PS, et al. Retrospective stratification of a consecutive cohort of prostate cancer patients treated with a combined regimen of external-beam radiotherapy and brachytherapy. Int J Radiat Oncol Biol Phys. 2001;49:1297-1303.
7. Barry MJ, Albertsen PC, Bagshaw MA, et al. Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management: A retrospective analysis. Cancer. 2001;91:2302-2314.
8. Do TM, Parker RG, Smith RB, Kagan AR. High-grade carcinoma of the prostate: A comparison of current local therapies. Urology. 2001;57:1121-1126.
9. Alexianu M, Weiss GH. Radical prostatectomy versus brachytherapy for early-stage prostate cancer. J Endourol. 2000;14:325-328.
10. Kupelian P, Katcher J, Levin H, et al. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: Therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. Cancer J Sci Am. 1997;3:78-87.
11. Brachman DG, Thomas T, Hilbe J, Beyer DC. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: Results from a single practice. Int J Radiat Oncol Biol Phys. 2000;48:111-117.
12. D'Amico AV, Whittington R, Kaplan I, et al. Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml. Int J Radiat Oncol Biol Phys. 1997;37:1053-1058.
13. Keyser D, Kupelian PA, Zippe CD, Levin HS, Klein EA. Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level < or = 10 ng/ml: Radiation therapy or surgery? Int J Radiat Oncol Biol Phys. 1997;38:723-729.
14. D'Amico AV, Whittington R, Kaplan I, et al. Equivalent 5-year bNED in select prostate cancer patients managed with surgery or radiation therapy despite exclusion of the seminal vesicles from the CTV. Int J Radiat Oncol Biol Phys. 1997;39:335-340.
15. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969-974.
16. Vicini FA, Horwitz EM, Kini VR, Stromberg JS, Martinez AA. Radiotherapy options for localized prostate cancer based upon pretreatment serum prostate-specific antigen levels and biochemical control: A comprehensive review of the literature. Int J Radiat Oncol Biol Phys. 1998;40:1101-1110.
17. Vicini FA, Horwitz EM, Gonzalez J, Martinez AA. Treatment options for localized prostate cancer based on pretreatment serum prostate specific antigen levels. J Urol. 1997;158:319-325.
18. Martinez AA, Gonzalez JA, Chung AK, et al. A comparison of external beam radiation therapy versus radical prostatectomy for patients with low risk prostate carcinoma diagnosed, staged, and treated at a single institution. Cancer. 2000;88:425-332.
19. Shipley WU, Thames HD, Sandler HM, et al. Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis. JAMA. 1999;281:1598-1604.
20. D'Amico AV, Desjardin A, Chung A, et al. Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy. Cancer. 1998;82:1887-1896.
21. Hanks GE. Radiotherapy or surgery for prostate cancer? Ten and fifteen-year results of external beam therapy. Acta Oncol. 1991;30:231-237.
22. Zietman AL. Radiation therapy or prostatectomy: An old conflict revisited in the PSA era. A radiation oncologist's viewpoint. Semin Radiat Oncol. 1998;8:81-86.
23. Zelefsky MJ, Wallner KE, Ling CC, et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol. 1999;17:517-522.
24. Stokes SH. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation. Int J Radiat Oncol Biol Phys. 2000;47:129-136.
25. Kirkpatrick J. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. J Insur Med. 1998;30:204-205.
26. Ramos CG, Carvalhal GF, Smith DS, Mager DE, Catalona WJ. Retrospective comparison of radical retropubic prostatectomy and 125 iodine brachytherapy for localized prostate cancer. J Urol. 1999;161:1212-1215.
27. American Society for Therapeutic Radiology and Oncology. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37:1035-1041.
28. Vicini FA, Kestin LL, Martinez AA. The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer [see comments]. Int J Radiat Oncol Biol Phys. 1999;45:553-561.
29. Lu J. Statistical aspects of evaluating treatment and prognostic factors for clinically localized prostate cancer. Semin Urol Oncol. 2000;18:83-92.
30. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin [see comments]. N Engl J Med. 1997;337:295-300.
31. Lawton CA, Winter K, Murray K, et al. Updated results of the Phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;49:937-946.
32. Pilepich MV, Winter K, John MJ, et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50:1243-1252.
33. Vicini FA, Abner A, Baglan KL, Kestin LL, Martinez AA. Defining a dose-response relationship with radiotherapy for prostate cancer: Is more really better?. Int J Radiat Oncol Biol Phys. 2001;51:1200-1208.
34. Horwitz EM, Hanlon AL, Pinover WH, Anderson PR, Hanks GE. Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques. Cancer. 2001;92:1281-1287.
35. Pollack A, Zagars GK, Smith LG, et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol. 2000;18:3904-3911.